Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  obinutuzumab
Find trials that include:  Any drugs shown
Results 1-19 of 19 for your search:
Start Over
A Study to Compare the Efficacy and Safety of Obinutuzumab + GDC-0199 Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: BO25323, NCI-2015-00926, 2014-001810-24, NCT02242942
Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 in Subjects With Previously Untreated CLL
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ACE-CL-007, NCI-2015-02261, NCT02475681
Lenalidomide and Obinutuzumab in Treating Patients with Relapsed Low-Grade Non-Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0261, NCI-2014-00943, ML28301, NCT01995669
Obinutuzumab and High-Dose Methylprednisolone in Treating Patients with Chronic Lymphocytic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UCSD GA101+HDMP, NCI-2014-01950, 140396, GA101-HDMP, NCT02229422
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Patients With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29365, NCI-2015-00293, 2014-001361-28, NCT02257567
Ibrutinib and Obinutuzumab in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 65 and over
Trial IDs: GA101 + Ibrutinib, NCI-2015-02052, 141106, NCT02315768
A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IPI-145-19, NCI-2015-01462, NCT02391545
A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Rituximab, Ibrutinib and Obinutuzumab in Subjects With Relapsed/Refractory CLL/SLL
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to less than 80
Trial IDs: CC-122-CLL-001, NCI-2015-01973, NCT02406742
Bcl-2 inhibitor GDC-0199 in Combination with Obinutuzumab and Ibrutinib in Treating Patients with Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-14266, NCI-2015-00252, ML29533, NCT02427451
Lenalidomide, Obinutuzumab, and CHOP in Treating Patients with Stage I-IV Diffuse Large B Cell Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-0069, NCI-2015-01517, NCT02529852
A Study of Obinutuzumab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29833, NCI-2015-02093, 2015-001998-40, NCT02611323
Bendamustine Hydrochloride, Obinutuzumab, and Dexamethasone in Treating Older Patients with Diffuse Large B-cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 70 and over
Trial IDs: IRB14-1120, NCI-2015-00355, NCT02420210
A Study of Venetoclax (GDC-0199; ABT-199) in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GP28331, NCI-2013-01154, 2012-002038-34, NCT01685892
A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29383, NCI-2014-02375, 2014-001812-21, NCT02220842
Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IPI-145-18, NCI-2015-00244, NCT02292225
ACP-196 in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-CL-003, NCI-2014-02555, NCT02296918
Ibrutinib and Obinutuzumab in Treating Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-283, NCI-2015-02275, ML29416, NCT02537613
Lenalidomide and Obinutuzumab in Treating Patients with Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0115, NCI-2015-00237, NCT02225275
Start Over